PCP: Difference between revisions
>Unity Changed wording of sentence concerning toxicity. |
>Unity Reordered section. |
||
Line 123: | Line 123: | ||
The long-term use of PCP may lead to schizophrenia-like psychotic episodes, severe lasting memory loss, disorganized thinking, depression, weight loss, liver abnormalities and rhabdomyolysis (skeletal muscle breakdown).<ref name="erowid">PCP Effects by Erowid | https://www.erowid.org/chemicals/pcp/pcp_effects.shtml</ref> | The long-term use of PCP may lead to schizophrenia-like psychotic episodes, severe lasting memory loss, disorganized thinking, depression, weight loss, liver abnormalities and rhabdomyolysis (skeletal muscle breakdown).<ref name="erowid">PCP Effects by Erowid | https://www.erowid.org/chemicals/pcp/pcp_effects.shtml</ref> | ||
It is very strongly recommended that one use extreme caution and [[responsible drug use|harm reduction]] practices when using this substance. For example, | |||
It is very strongly recommended that one use extreme caution and [[responsible drug use|harm reduction]] practices when using this | |||
*Users should avoid taking the drug multiple days in a row or becoming addicted to it as this increases the risk of severe adverse effects. | *Users should avoid taking the drug multiple days in a row or becoming addicted to it as this increases the risk of severe adverse effects. | ||
Line 135: | Line 130: | ||
*[[Compulsive redosing]] before one has fully sobered up is not recommended and can result in too high of a dose. | *[[Compulsive redosing]] before one has fully sobered up is not recommended and can result in too high of a dose. | ||
===Psychosis=== | |||
PCP has been reported to cause [[psychosis]] and mania at a significantly higher rate than other [[dissociative]]s such as [[ketamine]], [[diphenidine]], or [[MXE]]. Multiple scientific papers describe states of psychosis, mania, and/or delirium occurring after moderate to large doses of the drug were ingested. | |||
= | In one initial human trial, it was reported that one-sixth of the patients who had received anesthetic doses experienced acute psychosis.<ref name="one">http://archives.drugabuse.gov/pdf/monographs/21.pdf | Luisada, Paul V., M.D. "The Phencyclidine Psychosis: Phenomenology and Treatment." Phencyclidine (PCP) Abuse: An Appraisal. Rockville, Maryland: National Institute on Drug Abuse, 1978. pg. 241.</ref> In some cases, it took up to a week or more to resolve. Similar results (although less severe) were reported during trials using subanesthetic doses of PCP for pain relief.<ref name="two">Tasman, Allan, Jerald Kay, and Jeffrey A. Lieberman. Psychiatry. Chichester: John Wiley & Sons, 2003. Google Books. Wiley. Web. <https://books.google.com/books?id=l2KRBgAAQBAJ&pg=PT4957&lpg=PT4957&dq=Greifenstein+et+al.+1958%29.&source=bl&ots=s5CFdAfMzc&sig=GzsOq_N-V1qtahxyyHnKMJceEj0&hl=en&sa=X&ved=0ahUKEwji0pWTjNLKAhUBaD4KHTfqD0sQ6AEIHDAA#v=onepage&q=Greifenstein%20et%20al.%201958%29.&f=false>.</ref> | ||
Due to the risk of psychosis, it is not recommended to combine this substance with other substances, especially [[stimulant|stimulants]], [[psychedelic|psychedelics]], or other [[dissociative|dissociatives]] like [[MXE]] and [[DXM]]. | |||
===Neurological effects=== | ===Neurological effects=== | ||
Some studies found that, like other [[NMDA receptor antagonist|NMDA receptor antagonists]], PCP can cause brain damage called [https://en.wikipedia.org/wiki/Olney%27s_lesions Olney's lesions] in rats.<ref>Olney, J. W., Labruyere, J., & Price, M. T. (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science(Washington), 244(4910), 1360-1362. | https://www.ncbi.nlm.nih.gov/pubmed/2660263</ref><ref>Hargreaves, R. J., Hill, R. G., & Iversen, L. L. (1994). Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. In Brain Edema IX (pp. 15-19). Springer, Vienna. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/7976530</ref> Studies conducted on rats showed that high doses of the NMDA receptor antagonist dizocilpine caused reversible vacuoles to form in certain regions of the rats' brains. All studies of Olney's lesions have only been performed on non-human animals and may not apply to humans. One unpublished study by Frank Sharp reportedly showed no damage by the NMDA antagonist [[ketamine]] (a similar drug) far beyond recreational doses<ref>Jansen, Karl. Ketamine: Dreams and Realities. MAPS, 2004. ISBN 0-9660019-7-4</ref> but its validity is controversial since it was never published. | Some studies found that, like other [[NMDA receptor antagonist|NMDA receptor antagonists]], PCP can cause brain damage called [https://en.wikipedia.org/wiki/Olney%27s_lesions Olney's lesions] in rats.<ref>Olney, J. W., Labruyere, J., & Price, M. T. (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science(Washington), 244(4910), 1360-1362. | https://www.ncbi.nlm.nih.gov/pubmed/2660263</ref><ref>Hargreaves, R. J., Hill, R. G., & Iversen, L. L. (1994). Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. In Brain Edema IX (pp. 15-19). Springer, Vienna. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/7976530</ref> Studies conducted on rats showed that high doses of the NMDA receptor antagonist dizocilpine caused reversible vacuoles to form in certain regions of the rats' brains. All studies of Olney's lesions have only been performed on non-human animals and may not apply to humans. | ||
One unpublished study by Frank Sharp reportedly showed no damage by the NMDA antagonist [[ketamine]] (a similar drug) far beyond recreational doses<ref>Jansen, Karl. Ketamine: Dreams and Realities. MAPS, 2004. ISBN 0-9660019-7-4</ref> but its validity is controversial since it was never published. | |||
PCP has also been shown to cause schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate levels in the rat brain, which are detectable both in living rats and upon necropsy examination of brain tissue.<ref>Reynolds, L. M., Cochran, S. M., Morris, B. J., Pratt, J. A., & Reynolds, G. P. (2005). Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophrenia research, 73(2), 147-152.(PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/15653257</ref> It also induces symptoms in humans that mimic schizophrenia.<ref>Murray, J. B. (2002). Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. The Journal of psychology, 136(3), 319-327. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/12206280</ref> | PCP has also been shown to cause schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate levels in the rat brain, which are detectable both in living rats and upon necropsy examination of brain tissue.<ref>Reynolds, L. M., Cochran, S. M., Morris, B. J., Pratt, J. A., & Reynolds, G. P. (2005). Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophrenia research, 73(2), 147-152.(PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/15653257</ref> It also induces symptoms in humans that mimic schizophrenia.<ref>Murray, J. B. (2002). Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. The Journal of psychology, 136(3), 319-327. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/12206280</ref> | ||
Line 156: | Line 153: | ||
*'''Hematuria''' - Hematuria is visible blood in the urine. | *'''Hematuria''' - Hematuria is visible blood in the urine. | ||
*'''Incontinence''' - This is the uncontrolled leakage of urine. | *'''Incontinence''' - This is the uncontrolled leakage of urine. | ||
===Dependence and abuse potential=== | |||
The chronic use of PCP can be considered [[Addiction potential::highly addictive with a high potential for adverse side effects such as psychosis]]. In comparison to other [[dissociative]]s, PCP has been reported to be more addictive than [[MXE]], [[diphenidine]], [[ephenidine]], and [[ketamine]]. | |||
When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance. | |||
Tolerance to many of the effects of PCP develops [[Time to full tolerance::with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). PCP presents cross-tolerance with [[Cross-tolerance::all [[dissociative|dissociatives]]]], meaning that after the consumption of PCP, all [[dissociative|dissociatives]] will have a reduced effect. | |||
===Dangerous interactions=== | ===Dangerous interactions=== |